2015 - Neonatal Pharmacology

Content Origination Date: May 14, 2015 ‐ Content Expiration Date: May 27, 2018


Total CE Credits:
31.50 - RN / NP (All RNs/Nurses except CA RNs)
31.50 - CA RN/CA BRN
16.50 - Pharmacology
31.50 - Physician
21.00 - Pharmacist


This online conference offers cutting edge information from some of the leading clinicians and researchers in neonatology. You will learn from these experts how to integrate best practices into your unit for a broad range of neonatal drugs, as well as managing care in the light of drug shortages. A faculty of experts in neonatal pharmacology who will challenge you with emerging evidence, problem-solve clinical issues, and provide new insights for day-to-day practice.

Program Manager: Kathryn Clayton, MSN, MBA

Disclosures: The Program Manager has nothing to disclose.

Standard: $260.00

Sessions

Preview Available

Compounding Considerations of Neonatal Parenteral Nutrition (Rx = .75 hr.) ACPE #0263-000-15-519-H01-P (.75 contact hr.)

Content Origination Date: May 14, 2015 ‐ Content Expiration Date: May 27, 2018

CE Credits: None available.

Learning Objectives:

  • Discuss what excipients should be avoided when compounding a PN for a neonate.
  • Describe the limitations of typical pediatric PN formulations as they relate to total nutrient admixtures.
  • Identify what components are prone to aluminum contamination and how to minimize it.

Speaker(s): Disclosures
  • B Braun, ​Advisory board; Fresenius Kabi, Consultant; Pronova/BASF, Consultant/research support; Sancilio, Consultant/research support




     
Standard: $15.00

Preview Available

Lipid Management Strategies in PNALD: Dose Minimization vs. Type of Oil (Rx = .75 hr.) ACPE #0263-000-15-521-H01-P (.75 contact hr.)

Content Origination Date: May 14, 2015 ‐ Content Expiration Date: May 27, 2018

CE Credits: None available.

Learning Objectives:

  • List the factors that contribute to the development of PNALD as they relate to lipid emulsions.
  • Describe the effectiveness of restricting conventional lipid emulsions in patients at risk for PNALD.
  • Identify the role of fish oil emulsions in the management of PNALD.

Speaker(s): Disclosures
  • B Braun, ​Advisory board; Fresenius Kabi, Consultant; Pronova/BASF, Consultant/research support; Sancilio, Consultant/research support
Standard: $15.00

Preview Available

Breastfeeding Problems: Managing Medication Use During Lactation (Rx = .75 hr.) ACPE #0263-000-15-522-H01-P (1 contact hr.) - Q&D (Rx = .25 hr.) - Faculty Panel

Content Origination Date: May 14, 2015 ‐ Content Expiration Date: May 27, 2018

CE Credits: None available.

Learning Objectives:

  • Answer common patient questions involving maternal medications and breastfeeding.
  • Navigate difficult clinical scenarios involving maternal medications and breastfeeding.
  • Make recommendations for immunotherapy and antidepressants for breastfeeding mothers.

Speaker(s): Disclosures
  • This speaker has nothing to disclose.
Standard: $15.00

Preview Available

Nutritional Emergencies in the ELBW (Rx = .75 hr.) ACPE #0263-000-15-520-H01-P (1 contact hr.) - Q&D (Rx = .25 hr.) - Faculty Panel

Content Origination Date: May 14, 2015 ‐ Content Expiration Date: May 27, 2018

CE Credits: None available.

Learning Objectives:

  • Review several nutritional emergencies in the ELBW and what can be done about them.
  • Discuss prevention to avoid having these emergent situations.
  • Discuss some best practice concepts from the literature.

Speaker(s): Disclosures
  • This speaker has nothing to disclose.
Standard: $15.00

Preview Available

Building Prevention Strategies to Reduce Risk of NEC (Rx = .5 hr.) ACPE #0263-000-15-523-H01-P (.75 contact hr.)

Content Origination Date: May 14, 2015 ‐ Content Expiration Date: May 27, 2018

CE Credits: None available.

Learning Objectives:

  • Identify the known pathophysiologic changes that occur in NEC in preterm infants.
  • List the possible ways that have been shown to reduce the incidence of NEC.
  • Define a practical pathway to develop best practices in your unit to reduce NEC from occurring.

Speaker(s): Disclosures
  • This speaker has nothing to disclose.
Standard: $15.00

Preview Available

Nutritional Considerations in Short Bowel Syndrome (Rx = .75 hr.) ACPE #0263-000-15-524-H01-P (1 contact hr.)

Content Origination Date: May 14, 2015 ‐ Content Expiration Date: May 27, 2018

CE Credits: None available.

Learning Objectives:

  • Describe how dietary manipulation can be used to achieve optimal outcomes in infants with intestinal failure (IF).
  • Describe what laboratory parameters should be monitored in the PN dependent infant with intestinal failure.
  • Discuss role for medical therapies to optimize fluid and nutrient absorption in infants with intestinal failure.

Speaker(s): Disclosures
  • B Braun, ​Advisory board; Fresenius Kabi, Consultant; Pronova/BASF, Consultant/research support; Sancilio, Consultant/research support
Standard: $15.00

Preview Available

Nutrition in the Care of Infants with HIE (Rx = .25 hr.) ACPE #0263-000-15-525-H01-P (.75 contact hr.)

Content Origination Date: May 14, 2015 ‐ Content Expiration Date: May 27, 2018

CE Credits: None available.

Learning Objectives:

  • List 3 common metabolic alterations seen in the acute phase of the care of infants with HIE.
  • Describe a feeding protocol that can be used with infants with HIE.
  • Cite one nutritional study in the treatment of these infants over the first year of life.

Speaker(s): Disclosures
  • This speaker has nothing to disclose.
Standard: $15.00

Preview Available

Optimal Nutritional Management After Discharge in the Term and Preterm Neonate (Rx = .5 hr.) - Q&D (Rx = .25 hr.) - Faculty Panel ACPE #0263-000-15-526-H01-P (1 contact hr.)

Content Origination Date: May 14, 2015 ‐ Content Expiration Date: May 27, 2018

CE Credits: None available.

Learning Objectives: 

  • List the limitations of our current nutritional discharge process.
  • Identify the areas in nutrition that are important to consider for the growing preterm infant.
  • Develop a framework that clearly creates a detailed nutritional discharge plan for your NICU.

Speaker(s): Disclosures
  • Abbott Nutrition, ​Speaker, Research; Mead Johnson Nutrition, Speaker; Nestle Nutrition, Speaker, Advisor; Medela/Acacia Neonatal, Speaker, Consultant, Advisor; Pedia Solutions, Shareholder, Advisor; Nutricia, Speaker; Infacare Pharmaceutical, Research Grant
Standard: $15.00

Preview Available

What's New in Neonatal Pharmacology and Drug Dosing? (Rx = .75 hr.) ACPE #0263-000-15-527-H01-P (.75 contact hr.)

Content Origination Date: May 15, 2015 ‐ Content Expiration Date: May 27, 2018

CE Credits: None available.

Learning Objectives:

  • Describe new dosing guidelines for at least 1 medication. 
  • Describe new safety information for at least 1 medication. 
  • Describe FDA final rule regarding drug labeling for use in pregnancy and lactation. 

Speaker(s): Disclosures
  • This speaker has nothing to disclose.
Standard: $15.00

Preview Available

Neonatal Drug Formulations: Safety Gains and Risks (Rx = .5 hr.) ACPE #0263-000-15-528-H01-P (1 contact hr.) - Q&D (Rx = .25 hr.) - Faculty Panel

Content Origination Date: May 15, 2015 ‐ Content Expiration Date: May 27, 2018

CE Credits: None available.

Learning Objectives:

  • Describe the legal and regulatory challenges to pharmaceutical compounding for neonates.
  • Describe clinical risks associated with pharmaceutical compounding for neonates.
  • List compounded neonatal medications with recently published formulations.

Speaker(s): Disclosures
  • This speaker has nothing to disclose.
Standard: $15.00

Preview Available

The Synagis Debate: RSV Risk, Revised Recommendations, and Rising Cost (Rx = .75 hr.) ACPE #0263-000-15-529-H01-P (.75 contact hr.)

Content Origination Date: May 15, 2015 ‐ Content Expiration Date: May 27, 2018

CE Credits: None available.

Learning Objectives:

  • Discuss the prevalence of RSV and risk of hospitalization from severe disease across all neonatal and infant populations. 
  • Analyze data regarding palivizumab efficacy and cost effectiveness. 
  • Review revised 2014 palivizumab recommendations and discuss validity of changes. 

Speaker(s): Disclosures
  • This speaker has nothing to disclose.
Standard: $15.00

Preview Available

Introduction of Probiotic Products into the NICU: Getting Past the Barriers and Using Processes for a Smoother Transition (Rx = .25 hr.) ACPE #0263-000-15-530-H01-P (1 contact hr.) - Q&D (Rx = .25 hr.) - Faculty Panel

Content Origination Date: May 15, 2015 ‐ Content Expiration Date: May 27, 2018

CE Credits: None available.

Learning Objectives:

  • Discuss the advantages of probiotics in the NICU to reduce the incidence of NEC.
  • Discuss the potential dangers of using probiotics in the NICU.
  • Describe the barriers in introducing probiotics in the NICU.

Speaker(s): Disclosures
  • This speaker has nothing to disclose.
Standard: $15.00

Preview Available

When to Start and When to Stop: Controversies on Caffeine Use in the NICU (Rx = .75 hr.) ACPE #0263-000-15-531-H01-P (.75 contact hr.)

Content Origination Date: May 15, 2015 ‐ Content Expiration Date: May 27, 2018

CE Credits: None available.

Learning Objectives:

  • Identify the primary indications for starting caffeine in premature infants.
  • Recognize the short-term and long-term benefits of caffeine in premature infants.
  • Recognize the role of caffeine in decreasing intermittent hypoxia in premature infants.

Speaker(s): Disclosures
  • This speaker has nothing to disclose.
Standard: $15.00

Preview Available

Vitamin A in the NICU: An Expensive Therapy for BPD Reduction. Is It Worth It? (Rx = .25 hr.) ACPE #0263-000-15-532-H01-P (1 contact hr.) - Q&D (Rx = .25 hr.) - Faculty Panel

Content Origination Date: May 15, 2015 ‐ Content Expiration Date: May 27, 2018

CE Credits: None available.

Learning Objectives:

  • Describe the mechanism used by Vitamin A to reduce the severity of BPD.
  • Describe the clinical evidence supporting the use of vitamin to reduce BPD.
  • Determine if the use of Vitamin A is cost effective and worthwhile in their NICU population.

Speaker(s): Disclosures
  • This speaker has nothing to disclose.
Standard: $15.00

Preview Available

Inhaled Medication Use in Chronic Lung Disease (Rx = .75 hr.) ACPE #0263-000-15-533-H01-P (.75 contact hr.)

Content Origination Date: May 15, 2015 ‐ Content Expiration Date: May 27, 2018

CE Credits: None available.

Learning Objectives:

  • Describe the rationale for use of inhaled medications in the NICU.
  • Recognize the potential toxicities of inhaled medications in the NICU.
  • Describe the evidence for clinical efficacy of inhaled medications.

Speaker(s): Disclosures
  • This speaker has nothing to disclose.
Standard: $15.00

Preview Available

Neonatal Abstinence Syndrome: Something Borrowed, Something New: Are There Best Therapies? (Rx = .75 hr.) ACPE #0263-000-15-534-H01-P (.75 contact hr.) - Q&D (Rx = .25 hr.) - Faculty Panel

Content Origination Date: May 15, 2015 ‐ Content Expiration Date: May 27, 2018

CE Credits: None available.

Learning Objectives:

  • Demonstrate improved understanding of current limitations of pharmacologic management of neonatal abstinence syndrome.
  • Have an improved knowledge base of current management options for treating neonatal abstinence.
  • Articulate the ethical and moral challenges and dilemmas in caring for mothers and infants exposed to illicit substances. 

Speaker(s): Disclosures
  • This speaker has nothing to disclose.
Standard: $15.00

Preview Available

Considerations for Diuretic Use and Electrolyte Supplementation in Chronic Lung Disease (Rx = .75 hr.) ACPE #0263-000-15-535-H01-P (1 contact hr.)

Content Origination Date: May 16, 2015 ‐ Content Expiration Date: May 27, 2018

CE Credits: None available.

Learning Objectives:

  • Review renal physiology in the pre-term and full-term neonate and discuss importance as related to diuretic effects. 
  • Analyze literature supporting or refuting use of diuretics in chronic lung disease. 
  • Describe advantages and disadvantages of individual agents utilized in electrolyte supplementation therapy. 

Speaker(s): Disclosures
  • This speaker has nothing to disclose.
Standard: $15.00

Preview Available

Current Neonatal Pain and Sedation Strategies: From Morphine to Dexmedetomidine (Rx = .75 hr.) ACPE #0263-000-15-536-H01-P (1 contact hr.) - Q&D (Rx = .25 hr.) - Faculty Panel

Content Origination Date: May 16, 2015 ‐ Content Expiration Date: May 27, 2018

CE Credits: None available.

Learning Objectives:

  • Discuss the effects of neonatal pain on brain development. 
  • Describe potential short- and long-term risks and benefits of morphine and dexmedetomidine in neonates. 
  • Providers will have increased knowledge on pain and sedation strategies in critically ill neonates. 

Speaker(s): Disclosures
  • This speaker has nothing to disclose.
Standard: $15.00

Preview Available

Neonatal Skin: Bacterial Colonization, Disinfection and Antimicrobial Bathing (Rx = .25 hr.) ACPE #0263-000-15-537-H01-P (.75 contact hr.)

Content Origination Date: May 16, 2015 ‐ Content Expiration Date: May 27, 2018

CE Credits: None available.

Learning Objectives:

  • Introduce the concept of the skin microbiome, and what is known about adults, children and neonatal skin microbiome. 
  • Discuss use of skin disinfectants in the NICU in terms of efficacy, toxicity and skin irritation. 
  • Review studies related to bathing the newborn with antimicrobial solutions and identify the pros and cons of this practice. 

Speaker(s): Disclosures
  • Johnson & Johnson Consumer Co., Member, professional advisory panel, recipient investigator-initiated grant; 3M, Sponsored speaker at international conferences
Standard: $15.00

Preview Available

Neonatal Neuroprotection: Current Treatment Strategies and Future Horizons (Rx = .5 hr.) ACPE #0263-000-15-538-H01-P (1 contact hr.) - Q&D (Rx = .25 hr.) - Faculty Panel

Content Origination Date: May 16, 2015 ‐ Content Expiration Date: May 27, 2018

CE Credits: None available.

Learning Objectives:

  • Describe the relationship between prematurity and the risk for neurodevelopmental impairment.
  • Discuss current neuroprotective strategies in neonates
  • Discuss new neonatal therapies aimed at promoting improved neurodevelopmental outcomes.

Speaker(s): Disclosures
  • This speaker has nothing to disclose.
Standard: $15.00

Preview Available

What is the Role for Steroids in Newborns with Cardiovascular Insufficiency? (Rx = .5 hr.) ACPE #0263-000-15-539-H01-P (.75 contact hr.)

Content Origination Date: May 16, 2015 ‐ Content Expiration Date: May 27, 2018

CE Credits: None available.

Learning Objectives:

  • Describe the basics of cortisol synthesis and physiology. 
  • Define relative adrenal insufficiency. 
  • Describe options for treatment of cardiovascular insufficiency.

Speaker(s): Disclosures
  • This speaker has nothing to disclose.
Standard: $15.00

Preview Available

Misadventures in Neonatal IV Therapy: Extravasations, Occluded CVCs, and CLABSIs (Rx = .5 hr.) ACPE #0263-000-15-540-H01-P (1 contact hr.) - Q&D (Rx = .25 hr.) - Faculty Panel

Content Origination Date: May 16, 2015 ‐ Content Expiration Date: May 27, 2018

CE Credits: None available.

Learning Objectives:

  • Discuss prevention and treatment of intravenous extravasation injuries in neonates. 
  • Describe occlusion of central venous catheters, including blood clotting and precipitates, and options for restoring patency. 
  • Identify effective strategies to reduce the incidence of catheter-related blood stream infections in the NICU. 

Speaker(s): Disclosures
  • Johnson & Johnson Consumer Co., Member, professional advisory panel, recipient investigator-initiated grant; 3M, Sponsored speaker at international conferences
Standard: $15.00

Preview Available

Practice Strategies for the Treatment of PPHN (Rx = .5 hr.) ACPE #0263-000-15-541-H01-P (.75 contact hr.)

Content Origination Date: May 16, 2015 ‐ Content Expiration Date: May 27, 2018

CE Credits: None available.

Learning Objectives:

  • Describe the pathophysiology of PPHN in the newborn infant. 
  • Describe the common causes of PPHN in the newborn infant. 
  • Describe treatment options for PPHN in the newborn infant. 

Speaker(s): Disclosures
  • This speaker has nothing to disclose.
Standard: $15.00

Preview Available

PDA: To Treat or Not to Treat? (Rx = .25 hr.) ACPE #0263-000-15-542-H01-P (1 contact hr.) - Q&D (Rx = .25 hr.) - Faculty Panel

Content Origination Date: May 16, 2015 ‐ Content Expiration Date: May 27, 2018

CE Credits: None available.

Learning Objectives:

  • Identify 5 clinically relevant lessons learned from the existing literature on PDA pharmacologic treatment.
  • Be able to articulate why the current treatment of PDAs is controversial.
  • Identify 3 future studies which will help clarify treatment decisions involving PDAs.

Speaker(s): Disclosures
  • This speaker has nothing to disclose.
Standard: $15.00